SPOTLIGHT -
Novel agents in the pipeline for DED
Agents in the pipeline for DED
Overlapping diseases and COVID-19's impact
Counseling and formulary concerns for DED therapies
Challenges in the management of DED
Treatments for aqueous dry eye
In-office procedures and patient resistance for DED treatments
How to treat meibomian gland dysfunction
The role of nutritional supplements and antibiotics in DED
Corticosteroids and Immunomodulators for the treatment of dry eye
Review of artificial tears for DED
OD and MD communication for optimal care
General Principles of Treatment of DED
Standard testing and assessment for DED
Diagnosis and overlooking asymptomatic patients with DED
Consequences and epidemiology of untreated dry eye
Introduction and overview
Why comanagement matters
Surgical therapy for dry eye disease
Surgical therapy’s role in dry eye disease